The target dose is achieved in more de novo HFrEF patients than prior HFrEF patients, and fewer had SAEs and permanent treatment discontinuation.De novo patients show faster and greater decreases in NT-proBNP and hs-TnT, and lower rates of HF and all-cause rehospitalization vs. prior HFrEF. This evidence concerns the gene NPPB and hydrops fetalis.